menu
    • menu
    [{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Centers For Disease Control","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Nitroxoline","moa":"MetAP2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Asieris Pharmaceuticals \/ Centers For Disease Control","highestDevelopmentStatusID":"6","companyTruncated":"Asieris Pharmaceuticals \/ Centers For Disease Control"},{"orgOrder":0,"company":"BeiGene","sponsor":"Asieris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Nitroxoline","moa":"||MetAP2","graph1":"Oncology","graph2":"Preclinical","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Asieris Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"BeiGene \/ Asieris Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals for Nitroxoline (TN)

    Menu

    Nitroxoline (TN)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Asieris Pharmaceuticals

                            China arrow
                            AACR Annual meeting
                            Not Confirmed

                            Asieris Pharmaceuticals

                            China arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitroxoline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Centers For Disease Control

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Asieris, CDC Sign Agreement for APL-1202 Under Expanded Access Program

                            Details : Asieris has entered into an agreement to collaborate with the CDC in the US on APL-1202 (nitroxoline), It is being investigated for the treatment of FLA infections.

                            Product Name : APL-1202

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 06, 2025

                            Lead Product(s) : Nitroxoline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Centers For Disease Control

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BeiGene

                            China arrow
                            AACR Annual meeting
                            Not Confirmed

                            BeiGene

                            China arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitroxoline,Tislelizumab

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Asieris Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Asieris and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of APL-1202 and Tislelizumab

                            Details : APL-1202 is an orally available reversible MetAP2 Inhibitor with anti-angiogenic, anti-tumor activities and is an immune microenvironment modulator. Study will evaluate the safety & efficacy of oral APL-1202 in combination with tislelizumab as neoadjuvan...

                            Product Name : APL-1202

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 05, 2021

                            Lead Product(s) : Nitroxoline,Tislelizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Asieris Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth